Healthcare Services company Krsnaa Diagnostics announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations: Rs 1,861 million vs Rs 1,663 million in Q4FY24 (Change: 12%) Other Income: Rs 44 million vs Rs 43 million in Q4FY24 Total Income: Rs 1,905 million vs Rs 1,706 million in Q4FY24 (Change: 12%) EBITDA: Rs 542 million vs Rs 441 million in Q4FY24 (Change: 23%) EBITDA Margin: 29% vs 27% in Q4FY24 EBIT: Rs 354 million vs Rs 299 million in Q4FY24 (Change: 18%) EBIT Margin: 16% vs 18% in Q4FY24 Profit After Tax (PAT): Rs 207 million vs Rs 187 million in Q4FY24 (Change: 11%) PAT Margin: 11% vs 11% in Q4FY24 Diluted EPS: Rs 6.30 vs Rs 5.70 in Q4FY24 (Change: 11%) FY25 Financial Highlights: Revenue from Operations: Rs 7,172 million vs Rs 6,196 million in FY24 (Change: 16%) Other Income: Rs 255 million vs Rs 168 million in FY24 Total Income: Rs 7,427 million vs Rs 6,364 million in FY24 (Change: 17%) EBITDA: Rs 1,958 million vs Rs 1,466 million in FY24 (Change: 34%) EBITDA Margin: 27% vs 24% in FY24 EBIT: Rs 1,273 million vs Rs 865 million in FY24 (Change: 47%) EBIT Margin: 17% vs 14% in FY24 Profit After Tax (PAT): Rs 776 million vs Rs 568 million in FY24 (Change: 37%) PAT Margin: 11% vs 9% in FY24 Diluted EPS: Rs 23.56 vs Rs 17.31 in FY24 (Change: 36%) Yash Mutha, Managing Director, said: “We are pleased to report the strongest Profit After Tax (PAT) growth since our listing, with PAT reaching Rs 776 million in FY25 a 37% YoY increase. This exceptional performance was driven by higher volumes and improved operational efficiency. Krsnaa is executing several strategic initiatives to diversify its revenue streams beyond its current B2G-focused model. As part of our transition to an asset-light business model, we have entered into strategic partnerships with Medikabazaar and United Imaging to procure over 30 imaging machines on a deferred payment basis. We are also expanding into high-end PET-CT (oncology care) services through investments in Apulki Healthcare. Additionally, we are leveraging the Krsnaa brand at PPP centres to penetrate the B2C market. These initiatives will drive sustained growth, improve realizations, and reduce capex intensity, thereby enhancing the return ratios of the business. Krsnaa has delivered impressive growth over the last five years and is well-positioned for continued growth. Our unique business model targets the underserved markets in tier 2–3 cities, offering significant volume growth potential, especially as more states adopt the PPP model for free diagnostic schemes. Our nationwide offerings in pathology and radiology mitigate concentration risk and create economies of scale. In FY25, Krsnaa achieved a remarkable 16% year-on-year revenue growth, reaching Rs 7,172 million. Increased awareness of our high-quality services, combined with competitive pricing, has led to a significant rise in patient volumes and test counts. On the financial front, EBITDA surged 34% YoY to Rs 1,958 million, with improved margins of 27%. Net profit rose 37% YoY to Rs 776 million, with net margins at 11%, reflecting our ongoing commitment to operational efficiency through strategic initiatives. We remain confident in sustaining this positive momentum in the quarters ahead. Looking forward, our senior management is fully committed to executing our growth strategies. We are actively expanding our participation in tenders and strengthening our pipeline to ensure sustained growth. With a clear vision and disciplined execution, we are poised to further solidify our market leadership.” Pallavi Bhatevara, Executive Director, said: “At Krsnaa Diagnostics Limited, we leverage the Public-Private Partnership (PPP) model to provide free diagnostic services across India, with a strong pan-India presence. We have established ourselves as a key player in delivering high-quality and affordable diagnostic services, which are essential for disease diagnosis, management, and prevention. These services form a fundamental pillar of the healthcare industry. The Indian diagnostics industry, historically fragmented with a network of unorganized players, has experienced steady growth. The market registered an 8% CAGR over the past five years, reaching approximately US$ 12 billion in FY24. Within this context, the organized segment, consisting of national and regional diagnostic chains, has outpaced the broader market, achieving a 12% CAGR. This makes diagnostics one of the fastest-growing segments in the Indian healthcare sector. However, despite this steady expansion, diagnostics penetration in India remains among the lowest globally, even when compared to other developing nations. Krsnaa's Free Diagnostics Services has already made significant strides. To date, 12 states and Union Territories (UTs) have adopted free pathology services through the PPP model, and 19 states/UTs have adopted free radiology services, highlighting substantial untapped potential. State-level allocations for diagnostics have grown at an 18% CAGR, significantly outpacing the broader industry growth rate. Krsnaa has effectively capitalized on these opportunities, securing pathology tenders in 8 out of 12 states and winning radiology tenders in 12 out of 19 states, resulting in an impressive 75% win-to-bid ratio. This strong performance positions Krsnaa Diagnostics as the leading PPP player, offering a fully integrated service portfolio across radiology, pathology, and teleradiology.” Result PDF